Medotilin (Choline Alfoscerate) 1000mg/4ml x 3 Ampoules

The instruction for medical use of Medotilin Torgovoye medicine a name Medotilin Mezhdunarodnoye the unlicensed name of Sincaline alfostserat the Dosage form Solution for injections of 1000 mg / 4 ml Structure One ampoule contains active agent - sincaline of the alfostserat of 1000 mg (it is equivalent to sincaline of the alfostserat of hydrate 1222.34) excipient - water for injections. Description Transparent, colourless or light yellow color solution. Pharmacotherapeutic group Drugs for treatment of diseases of nervous system others. Other parasympathomimetics. Sincaline alfostserat. The ATX N07AX02 code the Pharmacological Pharmacokinetics Medotilin properties easily gets through a blood-brain barrier, collects mainly in a brain (45% of g/m of concentration in blood plasma) and also in a liver and lungs. Removal is carried out mainly through lungs in the form of carbon dioxide (85%), other quantity is removed by kidneys and through intestines. Medotilin's pharmacodynamics - a cholinomimetic of the central action with primary influence on the central nervous system. Drug contains 40.5% of metabolic protected sincaline. Sincaline alfostserat in an organism under the influence of enzymes of a brain it is split on sincaline and alfostserat which biotransformirutsya to glycerophosphate. Sincaline participates in synthesis of acetylcholine, transferring nervous impulses and improving work of a brain, and glycerophosphate is a predecessor of phosphatidylsincaline of membranes of neurons. Medotilin improves a cerebral blood stream, strengthens metabolic processes in a brain, activates structures of a reticular formation of a brain and restores consciousness in a traumatic brain damage. Has preventive and corrective effect on factors of an involutional psychoorganic syndrome, such as change of phospholipidic structure of membranes of neurons and decrease in cholinergic activity. Indications - an acute period of a craniocereberal injury mainly with stem defeats (including at consciousness disturbance, coma) - disturbances of cerebral circulation on ischemic type (acute and recovery period) and hemorrhagic type (recovery period) - degenerative and involutional psychoorganic syndromes and consequences of cerebrovascular insufficiency, such as primary and secondary disturbances of mnestic functions which are characterized by memory disturbances, confusion of consciousness, a disorientation, decrease in motivation, initiative and ability to concentration of attention - change in the emotional and behavioural sphere: emotional lability, acrimony, decrease in interest, senile pseudo-melancholy - multiinfarctive dementia the Route of administration and doses Drug is intended for intramuscular and intravenous administration. At acute conditions in oil in a dose of 1 g (1 ampoule) in day or in/in - from 1 g to 3 g a day. At in in introduction the contents of 1 ampoule (4 ml) are parted in 50 ml of normal saline solution, infusion speed - 60-80 thaws/min. Treatment duration usually is 10 days, but if necessary treatment can be continued before emergence of positive dynamics. Side effects - nausea (result of stimulation of dofaminergichesky processes) - allergic reactions (rash, urticaria) As a rule, drug is well transferred at prolonged use of the Contraindication - hypersensitivity to drug components - pregnancy and the period of a lactation - children's and teenage age up to 18 years Medicinal interactions of Interactions of the drug Medotilin with other medicines is not described. The special instructions Use in pediatrics Are not present sufficient clinical experience on use of drug in children's practice. It is not recommended to use drug in pediatrics. The feature of influence of medicine on ability to run the vehicle or potentially dangerous Medotilin mechanisms does not affect ability of the patient to drive the car and to be engaged in potentially dangerous types of activity. Overdose Symptoms: nausea. Treatment: drug withdrawal, symptomatic treatment. A form of release and packing On 4 ml of drug in ampoules from glass. On 3 ampoules in blister strip packagings. On 1 blister strip packaging together with the instruction for medical use in the state and Russian languages place in a box of cardboard. To Store storage conditions at a temperature not above 25 °C. To store out of children's reach! A period of storage 4 years not to apply after an expiration date Prescription status According to the prescription the Producer/packer of A.Sh. Mefar Ilach Sanayii, (Ramazanolu Makh. Ensar Dzhad. No. 20, 34906 Kurtkyoy-Pendik / Istanbul/Turkey) Mefar İlaç Sanayii A.Ş., (Ramazanoğlu Mah. Ensar Cad. No: 20, 34906 Kurtköy-Pendik/İstanbul/Turkey). Owner of the registration certificate Uorld Meditsin Ilach Sang. ve Tidzh. A.Sh., Turkey the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from the consumer on quality of products (goods) of RK, Almaty, Suyunbaya 222 St. of B Ph. / fax: 8 (7272) 529090 Address of the organization responsible for post-registration observation of safety of medicine of TROKA-S PHARMA LLP, Almaty, Suyunbaya Avenue 222-b Cellular ph. +7 701 786 33 98, (24-hour access). e-mail: pvpharma@worldmedicine.kz